Digestive Health
In the recent study, the NORDBIOTIC™ probiotic strains have demonstrated benefits for gastrointestinal and digestive health
Table 1. Specification of strains (NORDBIOTIC™) used in the evaluated probiotic preparation.
Strain | CFU Per Capsule | Number |
---|---|---|
Bifidobacterium breve | 2.08 x 108 | BB010 |
Bifidobacterium longum | 1.39 x 108 | BL020 |
Bifidobacterium bifidum | 1.39 x 108 | BF030 |
Bifidobacterium lactis | 4.17 x 108 | BL040 |
Lactobacillus rhamnosus | 5.56 x 108 | LR110 |
Lactobacillus paracasei | 2.08 x 108 | LPC100 |
Lactobacillus acidophilus | 2.08 x 108 | LA120 |
Lactobacillus casei | 2.08 x 108 | LC130 |
Lactobacillus plantarum | 2. 08 x 108 | LP140 |
Streptococcus thermophilus | 2.08 x 108 | ST250 |
Total CFU | 2.50 x 109 |
Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, Kanarek E, Sowińska A, Cukrowska B. Nutrients. 2021 Feb 26;13(3):756
The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study
Irritable bowel syndrome (IBS) is one of the most common, yet still not fully understood, gastrointestinal disorders in adults
One suspected etiology involves intestinal dysbiosis, i.e. both quantitative and qualitative alterations in the intestinal microbiota composition, which affect the gut-brain axis.
The formulation composed of a mixture of Bifidobacterium and Lactobacillus strains reduced the pain severity and improved the quality of life, whereas the synbiotic formulation effectively improved bloating and had a beneficial effect on the general condition of the intestines. A systematic review and meta-analysis published in 2020 showed that high doses of single-strain formulations, particularly those containing Bifidobacterium or Lactobacillus strains, may be more effective in IBS patients. Other reports demonstrated a high efficacy of the new-generation probiotic Bacillus coagulans in IBS. Therefore, the main objective of this research project is to assess the efficacy of single-strain probiotics containing Bifidobacterium lactis or Bacillus coagulans in patients with IBS and SIBO.
Principi N, Cozzali R, Farinelli E, Brusaferro A, Esposito S. Gut dysbiosis and irritable bowel syndrome: The potential role of probiotics. J Infect. 2018, 76(2):111-120
FAO/WHO Consultations and Workshops. Safety assessment of foods derived from genetically modified microorganisms. Report of a Joint FAO/WHO Expert Consultation on Foods Derived from Biotechnology, 200, 11–29
Ford, A.C.; Harris, L.A.; Lacy, B.E.; Quigley, E.M.M.; Moayyedi, P. Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2018, 48: 1044–1060
Skrzydło-Radomańska B., Prozorow-Król B., Cichoż-Lach H., et al. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study. Nutrients 2021,13:756
Skrzydło-Radomańska B., Prozorow-Król B., Cichoż-Lach H., et al. The effectiveness of synbiotic preparation containing Lactobacillus and Bifidobacterium probioticstrains and short chain fructooligosaccharides in patients with diarrhea predominant irritable bowel syndrome-a randomized double-blind, placebo-controlled study. Nutrients 2020, 12:1999
Li B., Liang L.; Deng, H.; Guo, J.; Shu, H.; Zhang, L. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-Analysis. Front. Pharmacol. 2020, 11, 332
Gupta AK, Maity C. Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant]. Medicine (Baltimore). 2021, 22;100(3):e23641
NORDBIOTIC™ strains preparation
Subjects of our research in IBS and SIBO:
- B. lactis NORDBIOTIC™ BI040
- B coagulans NORDBIOTIC™ BC300